AstraZeneca sees 2022 growth as dividend increases

AstraZeneca sees 2022 growth as dividend increases

February 11, 2022: -On Thursday, AstraZeneca forecast higher 2022 sales and raised its annualized dividend after the drugmaker posted better-than-expected fourth-quarter profit as it gets a lift from its Covid-19 antibody treatment and cancer drugs.

But the London-listed company warned that gross profit margins from coronavirus products were expected to be less than the company average for this year. In contrast, sales for Covid-19 products were expected to decline by a percentage in the low-to-mid 20s.

AstraZeneca has said that low-income nations would continue to receive its vaccine on a no-profit basis after it started making a modest profit on the shot set up a separate unit to focus on its coronavirus efforts and different respiratory infections.

“AstraZeneca continued on its strong growth trajectory in 2021, five of our medicines crossing a new blockbuster threshold,” Chief Executive Pascal Soriot said.

The Anglo-Swedish drugmaker expected 2022 revenue to increase by a percentage in the high teens, with core earnings growing by a portion in the mid-to-high 20s. In 2021, overall sales jumped 38% to $37.42 billion at constant currency rates.

Analysts estimate $6.68 per share and sales of $42.73 billion, according to Refinitiv IBES data.

The company, seen by analysts as one of the fastest-growing significant drugmakers mainly thanks to new cancer therapies, also said it would top up its annualized dividend by $0.10 to $2.90, the first year-on-year increase in a decade.

Share on facebook
Share on google
Share on twitter
Share on linkedin

About Us

We provide the insights on leaders who are responsible for taking their organization to new heights, all the while bringing together a group of talented individuals.

Recent Posts

AstraZeneca sees 2022 growth as dividend increases